J Nathan Cantrell1, Mark R Waddle2, Maarten Rotman3, Jennifer L Peterson2, Henry Ruiz-Garcia2, Michael G Heckman3, Alfredo Quiñones-Hinojosa4, Steven S Rosenfeld5, Paul D Brown6, Daniel M Trifiletti7. 1. James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee. 2. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL. 4. Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL. 5. Department of Neuro-Oncology, Mayo Clinic, Jacksonville, FL. 6. Department of Radiation Oncology, Mayo Clinic, Rochester, MN. 7. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL; Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL. Electronic address: trifiletti.daniel@mayo.edu.
Abstract
OBJECTIVE: To identify the frequency and characteristics of long-term survivors of glioblastoma. PATIENTS AND METHODS: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. RESULTS: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). CONCLUSION: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
OBJECTIVE: To identify the frequency and characteristics of long-term survivors of glioblastoma. PATIENTS AND METHODS: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. RESULTS: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). CONCLUSION: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
Authors: Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms Journal: J Neurooncol Date: 2022-01-04 Impact factor: 4.130
Authors: Cesar A Garcia; Adip G Bhargav; Mieu Brooks; Paola Suárez-Meade; Sujan K Mondal; Natanael Zarco; Karim ReFaey; Mark Jentoft; Erik H Middlebrooks; Matija Snuderl; Anna Carrano; Hugo Guerrero-Cazares; Paula Schiapparelli; Rachel Sarabia-Estrada; Alfredo Quiñones-Hinojosa Journal: Mol Cancer Ther Date: 2021-08-31 Impact factor: 6.009
Authors: Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2020-03-09 Impact factor: 4.130